Glycated hemoglobin (HbA1c)It is the product of the combination of hemoglobin in red blood cells and blood sugar. It can reflect the average blood sugar level in the past 2-3 months and is an important indicator for diabetes diagnosis and long-term blood sugar monitoring. This article will start from five aspects: definition, generation mechanism, clinical significance, detection methods and influencing factors to help readers fully understand this key indicator.

The production mechanism of glycosylated hemoglobin: When the blood sugar concentration increases, the glucose in the blood will irreversibly combine with the N-terminus of the beta chain of hemoglobin to form glycated hemoglobin. This reaction does not require enzyme catalysis and is directly proportional to blood glucose concentration and duration. Since the average lifespan of red blood cells is 120 days, HbA1c can stably reflect blood sugar fluctuations over a longer period of time and has more reference value than instantaneous blood sugar testing.

clinical core values: According to the American Diabetes Association (ADA) guidelines, HbA1c ≥ 6.5% can be used as one of the diagnostic criteria for diabetes. For confirmed patients, controlling it below 7% can significantly reduce the risk of complications. It is worth noting that factors such as anemia and hemoglobin lesions may interfere with the test results, and comprehensive judgment needs to be combined with other indicators.

Detection technology comparison: The current mainstream detection methods include high performance liquid chromatography (HPLC) and immunoassay. HPLC has high precision but is expensive and is suitable for laboratory use; immunoassay is easy to operate and is more suitable for primary medical institutions. The following is a comparison of common detection methods:

Comprehensive application suggestions: Glycated hemoglobin testing should be performed every 3-6 months, and combined with daily blood sugar monitoring, the effect of sugar control can be fully evaluated. Testing equipment (such as Cobas c501, Architect ci8200) produced by Roche, Abbott and other manufacturers are widely used in medical institutions. It should be noted that pregnant women and those with abnormal hemoglobin need to use alternative indicators such as fructosamine.

Quote sources:
1. American Diabetes Association "Standards for Diagnosis and Treatment of Diabetes" (2023 Edition)
2. "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China" by the Diabetes Branch of the Chinese Medical Association
3. Clinical testing equipment manufacturers: Roche Diagnostics (Cobas series), Abbott Laboratories (Architect series)